Oka Aiko, Yuta Atsushi, Okawa Yukiko, Masuno Satoru, Tsunoda Takatsugu, Takahara Eriko, Terada Akihiko, Kanai Kenichi, Nagakura Hitoshi, Mimura Hideya, Arao Harumi, Ueyama Shigehiro, Ueyama Akiyo, Tokuda Reiko, Bamba Hitoshi, Nakazato Hidehisa, Nakazato Mahoko, Amesara Ryo, Nakai Shigeru, Araki Susumu, Sakaida Mayuko, Tokuriki Masaharu, Hama Takemitsu, Chiba Mayumi, Ikeda Hiroki, Togawa Akihisa, Tsuzuki Hideaki, Hyo Yukiyoshi, Niitsu Sumiko, Ohkawa Chikahisa, Nakamoto Setsuo, Takeo Tetsu, Kumanomidou Hiroshi, Kanai Kengo, Kitamura Hiroshi, Sugiura Ruka, Okano Mitsuhiro
Department of Otorhinolaryngology, Head and Neck Surgery, International University of Health and Welfare Narita Hospital.
Yuta Clinic.
Arerugi. 2023;72(9):1138-1146. doi: 10.15036/arerugi.72.1138.
Little is known whether sublingual immunotherapy using Japanese cedar pollen extract (cedar SLIT) is effective for not only Japanese cedar pollinosis but also Japanese cypress pollinosis. We investigated the prevalence rate of Japanese cypress pollinosis, efficacy of cedar SLIT on cypress pollinosis and patients' wish to receive cypress SLIT.
We investigated a multi-center (31 institutions), cross-sectional survey using a self-administrated questionnaire with four questions for patients received cedar SLIT aged from 5 to 69 years old.
2523 subjects were enrolled for analysis. 83.4% of them had pollinosis symptoms during cypress season before cedar SLIT. In such patients, 37.4% experienced lessened efficacy of cedar SLIT during cypress season. Both the prevalence of cypress pollinosis and the lessened efficacy of cedar SLIT on cypress pollinosis were significantly seen in western Japan as compared to eastern Japan. 76.1% of the subject having cypress pollinosis before SLIT wished to receive cypress SLIT if it is available.
A lessened efficacy of cedar SLIT during cypress season was broadly seen in Japan, and further showed a regional difference. Together with the finding of high wish by patients, these results suggest a development of cypress SLIT is desirable.
对于使用日本雪松花粉提取物的舌下免疫疗法（雪松舌下免疫疗法）是否不仅对日本雪松花粉症有效，而且对日本扁柏花粉症也有效，目前知之甚少。我们调查了日本扁柏花粉症的患病率、雪松舌下免疫疗法对扁柏花粉症的疗效以及患者接受扁柏舌下免疫疗法的意愿。
我们对多中心（31个机构）进行了一项横断面调查，采用自填式问卷，对5至69岁接受雪松舌下免疫疗法的患者提出了四个问题。
2523名受试者被纳入分析。其中83.4%的人在接受雪松舌下免疫疗法之前的扁柏季节有花粉症症状。在这些患者中，37.4%的人在扁柏季节期间雪松舌下免疫疗法的疗效降低。与日本东部相比，日本西部扁柏花粉症的患病率和雪松舌下免疫疗法对扁柏花粉症疗效降低的情况均显著。在接受舌下免疫疗法前患有扁柏花粉症的受试者中，76.1%的人表示如果有扁柏舌下免疫疗法，希望接受该疗法。
在日本，雪松舌下免疫疗法在扁柏季节疗效降低的情况普遍存在，并且还存在地区差异。结合患者的高意愿这一发现，这些结果表明开发扁柏舌下免疫疗法是可取的。
